COMMUNIQUÉS West-GlobeNewswire

TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss First Quarter 2026 Financial Results on May 8, 2026
07/05/2026
FREDERICK, Md., May 06, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report [...]
Totus Medicines Presents Early Phase 1b Clinical Data Demonstrating 100% Disease Control Rate and Class-Leading Safety for TOS-358 + Fulvestrant Doublet Therapy in HR+/HER2- Breast Cancer at ESMO Breast Cancer Annual Congress 2026
07/05/2026
TOS-358 is a covalent, pan-mutant, a -selective PI3K inhibitor designed to address key limitations of existing PI3K a therapies which include limited mutation coverage and poor tolerability First presentation of [...]
Vireo Growth Inc. to Release First Quarter Results on May 12, 2026
06/05/2026
MINNEAPOLIS, May 06, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today announced that it will release its financial results for its first quarter ended March 31, 2026 [...]
Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update
06/05/2026
On track to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Well-capitalized with $106.9 million in cash and cash equivalents as of March 31, 2026 SOUTH SAN FRANCISCO, Calif [...]
argenx to Present at BofA Securities 2026 Health Care Conference
06/05/2026
May 6, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen [...]
Sanuwave Will Host a Conference Call on May 13, 2026 at 8:30 AM (ET) to Present Q1 2026 Financial Results
06/05/2026
EDEN PRAIRIE, Minn., May 06, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live [...]
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
06/05/2026
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) will announce topline results from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of the Phase 1/2 [...]
Monthly information on share capital and company voting rights
06/05/2026
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, May 06, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the capital [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
06/05/2026
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 06 mai 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
06/05/2026
PiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line setting on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission [...]
Zelluna ASA activates first clinical site for ZIMA-101, marking entry into clinical execution
06/05/2026
Oslo, 6 May 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announces that the first [...]
electroCore Announces First Quarter 2026 Financial Results
06/05/2026
First quarter 2026 net sales of $9.6 million, an increase of 43% over $6.7 million in the first quarter 2025 Net loss of $5.3 million with Adjusted EBITDA net loss improving 24% from prior-year period to $2.3 million [...]
Alpha Honey Gummies Claims Evaluated: The AlphaHoney Male Enhancement Ingredients for Virility-Enhancing Performance Support
06/05/2026
How Muira Puama, Maca, Ashwagandha, L-Arginine, and Tribulus Terrestris Work in the AlphaHoney Male Performance Gummy Formula for Libido, Testosterone Support, and Circulation in 2026 Largo, FL, May 06, 2026 (GLOBE [...]
Precipio Announces Q1-2026 Shareholder Update Call
06/05/2026
Conference Call will be held on May 18th, 2026, at 5:00 PM EST NEW HAVEN, Conn., May 06, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q1-2026 [...]
Alvotech Q1 2026 Financial Results
06/05/2026
Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB) Financial Highlights A supplemental long ‑ form earnings release providing additional operational details and business update for Q1 2026 is available at: [...]
Gala Health Under Investigation: High-Quality Compounded GLP-1 Weight Loss & Hormone Therapy HRT Support
06/05/2026
Compounded Tirzepatide, Semaglutide, and Bioidentical HRT Telehealth Plans Through Gala GLP-1: Licensed Providers, $149/Mo Pricing, and All-50-States Access Explained for 2026 Wilmington, Delaware, May 06, 2026 (GLOBE [...]
iMDx to Release First Quarter 2026 Results on May 13, 2026
06/05/2026
NASHVILLE, Tenn., May 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report first quarter 2026 financial results after the market closes on [...]
Alvotech Q1 2026 Financial Results
06/05/2026
REYKJAVIK, Iceland, May 06, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB) Financial Highlights A supplemental long ‑ form earnings release providing additional operational [...]
ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
06/05/2026
1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year 1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year 1Q 2026 Adjusted Net Income ( 1) of $40.7 Million, 22% Year-Over-Year Growth [...]

Pages